NCT03591367

The Potential Role Of MicroRNA-155 And Telomerase Reverse Transcriptase In Diagnosis Of Non-Muscle Invasive Bladder Cancer And Their Pathological Correlation

Completed NA Last updated 4 November 2019

What this trial tests

NA trial testing MicroRNAs-155 in Bladder Cancer in 115 participants. Completed in 1 May 2019.

Timeline

1 August 2018

Primary endpoint
1 May 2019

1 May 2019

Quick facts

Lead sponsor	Mansoura University
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	diagnostic
Enrollment	115
Start date	1 August 2018
Primary completion	1 May 2019
Estimated completion	1 May 2019
Sites	1 location across Egypt

Drugs / interventions tested

• MicroRNAs-155
• Human telomerase reverse transcriptase

Conditions studied

• Bladder Cancer — all drugs for Bladder Cancer →
• Bladder Disease — all drugs for Bladder Disease →
• Bladder Neoplasm — all drugs for Bladder Neoplasm →
• Micro-RNA — all drugs for Micro-RNA →

Sponsor

Mansoura University

Who can join

18 and older, any sex, with Bladder Cancer or Bladder Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

We try to assess the potential role of telomerase reverse transcriptase and MicroRNA (miR-155) in diagnosis of non-muscle-invasive bladder cancer and their correlation with stage and grade of the tumor.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

1. MicroRNA: trends in clinical trials of cancer diagnosis and therapy strategies.
   Kim T, Croce CM. · · 2023 · cited 270× · PMID 37430087 · DOI 10.1038/s12276-023-01050-9
2. Noncoding RNAs in cancer therapy resistance and targeted drug development.
   Wang WT, Han C, Sun YM, Chen TQ, et al · · 2019 · cited 198× · PMID 31174564 · DOI 10.1186/s13045-019-0748-z
3. Tumor-derived extracellular vesicles: reliable tools for Cancer diagnosis and clinical applications.
   Rahbarghazi R, Jabbari N, Sani NA, Asghari R, et al · · 2019 · cited 160× · PMID 31291956 · DOI 10.1186/s12964-019-0390-y
4. The crosstalk between reactive oxygen species and noncoding RNAs: from cancer code to drug role.
   Zuo J, Zhang Z, Li M, Yang Y, et al · · 2022 · cited 43× · PMID 35081965 · DOI 10.1186/s12943-021-01488-3
5. Mitochondrial microRNA (MitomiRs) in cancer and complex mitochondrial diseases: current status and future perspectives.
   Purohit PK, Saini N. · · 2021 · cited 42× · PMID 33084945 · DOI 10.1007/s00018-020-03670-0
6. Tumor heterogeneity and the potential role of liquid biopsy in bladder cancer.
   Huang HM, Li HX. · · 2021 · cited 39× · PMID 33377623 · DOI 10.1002/cac2.12129
7. The role of noncoding RNAs in epithelial cancer.
   Agostini M, Ganini C, Candi E, Melino G. · · 2020 · cited 37× · PMID 32194993 · DOI 10.1038/s41420-020-0247-6
8. Decoding the Promise and Challenges of miRNA-Based Cancer Therapies: An Essential Update on miR-21, miR-34, and miR-155.
   Qian H, Maghsoudloo M, Kaboli PJ, Babaeizad A, et al · · 2024 · cited 29× · PMID 39512697 · DOI 10.7150/ijms.102123